- Home
- GERN vs ACAD Comparison
GERN vs ACAD Comparison
Compare GERN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- ACAD
- Stock Information
- Founded
- GERN 1990
- ACAD 1993
- Country
- GERN United States
- ACAD United States
- Employees
- GERN N/A
- ACAD N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- GERN Health Care
- ACAD Health Care
- Exchange
- GERN Nasdaq
- ACAD Nasdaq
- Market Cap
- GERN 2.5B
- ACAD 2.8B
- IPO Year
- GERN 1996
- ACAD 2004
- Fundamental
- Price
- GERN $2.89
- ACAD $17.57
- Analyst Decision
- GERN Strong Buy
- ACAD Buy
- Analyst Count
- GERN 10
- ACAD 19
- Target Price
- GERN $7.15
- ACAD $26.17
- AVG Volume (30 Days)
- GERN 14.8M
- ACAD 4.3M
- Earning Date
- GERN 02-26-2025
- ACAD 02-25-2025
- Dividend Yield
- GERN N/A
- ACAD N/A
- EPS Growth
- GERN N/A
- ACAD N/A
- EPS
- GERN N/A
- ACAD 0.78
- Revenue
- GERN $29,480,000.00
- ACAD $929,236,000.00
- Revenue This Year
- GERN $31,478.06
- ACAD $36.78
- Revenue Next Year
- GERN $290.89
- ACAD $8.19
- P/E Ratio
- GERN N/A
- ACAD $22.63
- Revenue Growth
- GERN 9199.68
- ACAD 47.06
- 52 Week Low
- GERN $1.64
- ACAD $14.15
- 52 Week High
- GERN $5.34
- ACAD $29.29
- Technical
- Relative Strength Index (RSI)
- GERN 25.84
- ACAD 52.06
- Support Level
- GERN $2.80
- ACAD $16.61
- Resistance Level
- GERN $3.68
- ACAD $18.23
- Average True Range (ATR)
- GERN 0.18
- ACAD 0.74
- MACD
- GERN -0.04
- ACAD -0.05
- Stochastic Oscillator
- GERN 10.23
- ACAD 36.59
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.